ALK and squamous cell carcinoma: Although these first- and new generation TKIs improved the survival for patients with non-squamous cell carcinoma and EGFR or ALK mutation (33), these patient populations accounted for a low percentage of the overall NSQ group (approx. 10% and 4% based on clinical references).